A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
Price : $35 *
At a glance
- Drugs Losmapimod (Primary) ; Moxifloxacin
- Indications Acute coronary syndromes; Atherosclerosis; Chronic obstructive pulmonary disease; Dyslipidaemias
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Mar 2013 Planned number of patients changed from 60 to 52 as reported by ClinicalTrials.gov.
- 22 Jan 2013 New trial record